BAY 249716
Based on 1 Customer Validation
BAY 249716 stabilizes all three p53 protein variants. BAY 249716 also has antitubercular activity (IC90: <0.10 μg/mL for Tuberculosis).
For research use only. We do not sell to patients.
- Purity: 99.03%
- CAS No.: 696628-24-7
- Formula: C13H9ClN4S
- Molecular Weight:288.76
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antibacterial Compound Library
HY-L049
-
Ferroptosis Compound Library
HY-L051
-
Pyroptosis Compound Library
HY-L059
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-tuberculosis Compound Library
HY-L142
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774.A1 | IC50 |
0.09 μM
Compound: 30
|
Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase reporter gene infected in mouse J-774A1 cells assessed as inhibition of amastigote stage formation incubated for 72 hrs by luminometry
Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase reporter gene infected in mouse J-774A1 cells assessed as inhibition of amastigote stage formation incubated for 72 hrs by luminometry
|
[PMID: 26318065] |
| KB | CC50 |
98.6 μM
Compound: 30
|
Cytotoxicity in human KB cells assessed as cell viability incubated for 72 hrs by MTT assay
Cytotoxicity in human KB cells assessed as cell viability incubated for 72 hrs by MTT assay
|
[PMID: 26318065] |
Chemical Information
-
CAS No. 696628-24-7
-
Appearance Solid
-
Molecular Weight 288.76
-
Formula C13H9ClN4S
-
Color Light brown to brown
-
SMILES
ClC1=CN=C(NC2=NC(C3=CC=CC=N3)=CS2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (346.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.66 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lemos C, et al. Identification of Small Molecules that Modulate Mutant p53 Condensation. iScience. 2020 Sep 1;23(9):101517. [Content Brief]
[2]. Ananthan S, et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb). 2009 Sep;89(5):334-53. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4631 mL | 17.3154 mL | 34.6308 mL | 86.5771 mL |
| 5 mM | 0.6926 mL | 3.4631 mL | 6.9262 mL | 17.3154 mL | |
| 10 mM | 0.3463 mL | 1.7315 mL | 3.4631 mL | 8.6577 mL | |
| 15 mM | 0.2309 mL | 1.1544 mL | 2.3087 mL | 5.7718 mL | |
| 20 mM | 0.1732 mL | 0.8658 mL | 1.7315 mL | 4.3289 mL | |
| 25 mM | 0.1385 mL | 0.6926 mL | 1.3852 mL | 3.4631 mL | |
| 30 mM | 0.1154 mL | 0.5772 mL | 1.1544 mL | 2.8859 mL | |
| 40 mM | 0.0866 mL | 0.4329 mL | 0.8658 mL | 2.1644 mL | |
| 50 mM | 0.0693 mL | 0.3463 mL | 0.6926 mL | 1.7315 mL | |
| 60 mM | 0.0577 mL | 0.2886 mL | 0.5772 mL | 1.4430 mL | |
| 80 mM | 0.0433 mL | 0.2164 mL | 0.4329 mL | 1.0822 mL | |
| 100 mM | 0.0346 mL | 0.1732 mL | 0.3463 mL | 0.8658 mL |
BAY 249716 Related Classifications
HY-160922 Related Classifications
Powered by Bioz